BRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III

* Theratechnologies-Abstract submitted by its partner,

Taimed Biologics, for 24-week study of Ibalizumab phase III

study has been selected for late breaker presentation

Source text for Eikon:...

Read more